Q-omics provides the consensus-scored MSMO1 profile across patient tissues and cancer cell-line models. MSMO1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MSMO1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, MSMO1 protein abundance shows 18,569 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, LUAD, and UCEC as cancer lineages where MSMO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSMO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSMO1 survival associations across molecular data types. MSMO1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSMO1 RNA expression–survival associations across cancer types. High MSMO1 expression shows unfavorable associations in HNSC, CESC, UVM, PAAD, MESO and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MSMO1 RNA expression.
This table summarizes MSMO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MSMO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSMO1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in BLCA, COAD, THCA and BRCA. The LUAD box plot shows higher MSMO1 RNA expression in normal versus tumor tissue (log2 FC = −1.265, t-test p < 0.001).
This table shows molecular features associated with MSMO1 in patient tissues and cancer cell lines. In patient samples, MSMO1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MSMO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
